New board member for Siegfried
At the Shareholders’ Meeting scheduled for 18 April 2013, the Board of Directors of Siegfried Holding AG will propose the appointment to the Board of Colin Bond, Chief Financial Officer of Evotec AG.
Colin Bond, 52, is a citizen of Great Britain and Switzerland. In 2010, he joined Hamburg-based Evotec AG as group Chief Financial Officer and member of the management board. The company is listed on the Frankfurt Stock Exchange as part of TecDax and provides a wide range of research and development services in the field of pharmaceutical ingredients. Following career stations as a pharmacist, chartered accountant and management consult-ant, he worked for 25 years as Chief Financial Officer for several international companies in various industries, of which 11 years for Great Lakes Chemical Corporation, today Chemtura, a US-based global specialty chemicals company.
Colin Bond holds a university degree in pharmacy from the University of Aston, Birmingham, and a MBA degree from London Business School.
Most read news
Organizations
Other news from the department people

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
Most read news
More news from our other portals
Last viewed contents

Cow's milk protein beta-lactoglobulin prevents allergies - New key molecule for the so-called protective farm effect
Category:Health_maintenance_organizations

Blood tests could predict survival odds for patients with metastatic cancer - By measuring the proportion of DNA in the bloodstream that comes from a tumor, liquid biopsies may be able to guide treatment discussions
Alizé Pharma signs research collaboration and license option agreement with Lilly - Companies to collaborate on an exclusive basis on Alizé Pharma's unacylated ghrelin (AZP-01) program for the treatment of Type II diabetes

Novel quantum dots enhance cell imaging
SYGNIS Pharma AG approves Combination of Businesses with X-Pol Biotech - Comprehensive strategic realignment
Crucell Announces Registration of Hepavax-Gene in China

'Dominating' fungus could be solution to producing more biofuels and chemicals
Powdery mildew at an evolutionary dead end
